Evidence map›Paper›PMID 42359160›Full record

ArticleInternational journal of endocrinology2026

Repurposing the Antibiotic Tigecycline to Inhibit Tumor Growth and Hormone Secretion in Somatotroph Pituitary Neuroendocrine Tumors.

Zhiqian Yang, Yang Liu, Dapeng Wu, Bin Xu, Shengfa Zeng, Wei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiqian YangDepartment of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Guangzhou, 510080, China, gdpu.edu.cn.ORCID https://orcid.org/0000-0002-0323-2814
Yang LiuDepartment of Neurosurgery, Huai'an Hospital, No. 19 Shanyang Road, Huai'an, 223220, China.ORCID https://orcid.org/0009-0007-0963-5458
Dapeng WuDepartment of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Guangzhou, 510080, China, gdpu.edu.cn.ORCID https://orcid.org/0009-0006-1375-1702
Bin XuDepartment of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Guangzhou, 510080, China, gdpu.edu.cn.ORCID https://orcid.org/0009-0005-3583-4501
Shengfa ZengDepartment of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Guangzhou, 510080, China, gdpu.edu.cn.ORCID https://orcid.org/0009-0002-6173-0237
Wei ZhangDepartment of Neurosurgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19 Nonglinxia Road, Guangzhou, 510080, China, gdpu.edu.cn.ORCID https://orcid.org/0000-0002-4832-6961

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This investigation employed the rat GH3 somatotroph pituitary neuroendocrine tumor (PitNET) cell line to assess the effects of the antibiotic tigecycline and to preliminarily elucidate its potential molecular mechanisms. Methods: GH3 cells were exposed to tigecycline ranging from 6.25 to 100 μM. Cell viability and IC Results: Tigecycline dose and time dependently suppressed GH3 cell proliferation, with IC Conclusion: These findings indicate that tigecycline exerts potent antiproliferative and antisecretory effects on GH3 cells, likely through Akt/mTOR pathway inhibition, cell cycle arrest, and apoptosis induction. These results provide an experimental foundation for considering tigecycline as a potential therapeutic agent for GH-secreting PitNET.

Indexed as

Akt/mTOR signaling pathwaygrowth hormonesomatotroph pituitary neuroendocrine tumor (PitNET)tigecycline

Identifiers

PMID42359160
PMCPMC13291717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.